Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: Analysis of outcome and prognostic factors after conventional salvage therapy

European Journal of Haematology

Volumn 68, Issue 5, 2002, Pages 289-298

  Vassilakopoulos, Theodoros P ^a   Angelopoulou, Maria K ^a   Siakantaris, Marina P ^a   Kontopidou, Flora N ^a   Dimopoulou, Maria N ^a   Boutsis, Dimitrios E ^a   Anargyrou, Konstantinos ^a   Kokoris, Styliani I ^a   Giannakakis, Antonia ^a   Karkantaris, Christos ^a   Kyrtsonis, Marie Christine ^a   Tsaftaridis, Panayiotis ^a   Rombos, John ^a   Variamis, Eleni ^a   Korkolopoulou, Pinelopi ^a   Kittas, Christos ^a   Pangalis, Gerassimos A ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chemotherapy; Combined modality; Hodgkin's lymphoma; Prognostic factors; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SALVAGE THERAPY; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036348605     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01721.x     Document Type: Article

References (48)

1. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients
2. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's Disease
3. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease
4. Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease (HD)
5. Twenty years of MOPP therapy for Hodgkin's disease
6. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD. A report from the National Cancer Institute of Canada clinical trials group
7. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results
8. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy
9. MOPP/ABV versus ABVD for advanced Hodgkin's disease - A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC)
10. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
11. Prognostic factors in advanced stage Hodgkin's lymphoma. The significance of the number of involved anatomic sites
12. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
13. Primary refractory Hodgkin's disease
14. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Study Group
15. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD
16. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970-88
17. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients
18. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
19. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission
20. Late relapses in Hodgkin's disease. Outcome of patients relapsing more than twelve months after primary chemotherapy
21. Salvage radiotherapy following chemotherapy failure in Hodgkin's disease - What is its role?
22. Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease
23. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure
24. Salvage radiotherapy in recurrent Hodgkin's disease
25. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure
26. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin's disease in relapse after initial combination chemotharpy
27. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group
28. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
29. Intensive therapy with cyclophosphamide, carmustine, etoposide (cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
30. Etoposide, vinblastine, and doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP
31. The length of the first complete remission (1-6 months; 7-12 months; > 12 months) does not predict outcome following BEAM and autotransplantation for Hodgkin's disease in first relapse
32. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease
33. Combination chemotherapy with mitoxantrone, etoposide, vindezine and bleomycin as salvage therapy for patients with Hodgkin's disease
34. Hodgkin's disease: Effective oral chemotherapy in patients resistant to intravenous therapy
35. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group
36. Non-parametric estimation from incomplete observations
37. Asymptotically efficient rank invariant test procedures
38. Regression models and life tables
39. Pathophysiology of Hodgkin's disease: Functional and molecular aspects
40. Intensive salvage therapywith high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy. Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial
41. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial
42. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease; a randomised trial
43. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma
44. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
45. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome
46. Bcl-2 expression in Hodgkin-Reed-Sternberg cells (HRS) of patients with classical Hodgkin's disease is associated with lower progression-free survival and survival
47. 2-microglobulin in patients with Hodgkin's lymphoma
48. Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease